N-(4-(Benzyloxy)benzylidene)-4-fluoroaniline

We are N-(4-(Benzyloxy)benzylidene)-4-fluoroaniline CAS:70627-52-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: N-(4-(Benzyloxy)benzylidene)-4-fluoroaniline
CAS.NO:  70627-52-0
Synonyms:
Benzenamine, 4-fluoro-N-[[4-(phenylmethoxy)phenyl]methylene]-
N-(4-fluorophenyl)-1-(4-phenylmethoxyphenyl)methanimine
FR DNU1R DO1R
1-[4-(Benzyloxy)phenyl]-N-(4-fluorophenyl)methanimine

Molecular Formula: C9H5ClO2S
Molecular Weight:   212.653

Physical and Chemical Properties:
Density: 1.07 g/cm3
Boiling point: 455.2ºC at 760 mmHg
Melting point: 136-138ºC
Flash point: 229.1±25.9 °C
Refractive index: 1.558

Specification:
Appearance: Light yellow flaky crystal
Purity:≥99.0%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Ezetimibe CAS:163222-33-1.

Related News: It is delivered to hospitals and pharmacies until it reaches the patient.2- (clorometil) -4-metilquinazolina CAS:109113-72-6 It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.5442-91-1 Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies.(R) – (+) – 1-butin-3-ol CAS:42969-65-3 Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies.Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.